Table 1.

Baseline Patient Demographic and Clinical Characteristics in HGG and Solid Tumor Studies

Characteristic	HGG		Solid Tumors5		P
	No. of Patients (N = 327)	%	No. of Patients (N = 3,104)	%
Age, years					—
Median	52		58
Range	18-86		18-87
Sex					< .001
Men	204	62	1,539	50
Women	123	38	1,565	50
ECOG performance status					< .001
Median	1		1
0	40	12	892	29
1	213	65	2,056	66
≥ 2	74	23	156	5
Median No. of prior chemotherapies					< .001
0-2	1	95	860	28
≥ 3	311	5	1,539	72
Missing	16		5
Resection	73	22	—	—	—
Biopsy	254	78
Prior radiation therapy					< .001
Yes	318	97	1,446	47
No	0	0	1,653	53
Missing	9	3	5	0
Concurrent AEDs	259	100	NA	NA	—
EIAED	168	65
Non-EIAED	91	35
WBC, × 109/L					—
Median	6.6		6.7
Range	2.3-17.9		2.1-38.2
Hemoglobin, g/dL					—
Median	14		12.2
Range	13-17		8-17.3
Platelets, × 109/L					—
Median	218		255
Range	90-636		78-1,114
AST, U/L					—
Median	21		27
Range	18-75		7-176
ALT, U/L					—
Median	29		23
Range	7-157		2-170
Alkaline phosphatase					—
Median	80		102
Range	3-225		25-10,405
Total bilirubin, mg/dL					—
Median	0.5		0.5
Range	0.1-2		0.1-1.9
Creatinine
Median	0.8				—
Range	0.4-1.5
PT, seconds					—
Median	11.7
Range	1.1-34.7
PTT, seconds					—
Median	26
Range	12.7-42.4
Brain	327	100	8	< 1	< .001
Glioblastoma	207	63	—
Nonglioblastoma	120	37	—
Drug class					< .001
Molecular	222	67	1,345	43
Cytotoxic	105	32	575	19
Molecular and cytotoxic	0	0	1,184	38
No. of study drugs	3,270				< .001
1		100	1,137	37
≥ 2		0	1,967	63

NOTE. The χ² test was used for all categorical variables. Standard deviations were not published for solid tumor studies, and statistical comparisons between data sets were not performed.

Abbreviations: AED, antiepileptic drug; EIAED, enzyme-inducing antiepileptic drug; ECOG, Eastern Cooperative Oncology Group; HGG, high-grade glioblastoma; NA, not applicable; PT, prothrombin time; PTT, partial thromboplastin time.